Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III rituximab combination therapy for antibody-mediated rejection after kidney transplantation
jRCT2080224105Phase 3Completed
- Sponsor
- Nippon Zenyaku Kogyo Co., Ltd.
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rituximab in humoral rejection, sponsored by Nippon Zenyaku Kogyo Co., Ltd. Started Oct 2018; status: completed.
02
Drugs
rituximab
03
Conditions
humoral rejection
Beyond the preview
Go deeper on jRCT2080224105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224105.